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Objective: To determine the diagnostic value of a ghrelin test in the diagnosis of GH deficiency (GHD)
shortly after aneurysmal subarachnoid hemorrhage (SAH).
Design: Prospective single-center observational cohort study.
Methods: A ghrelin test was assessed after the acute phase of SAH and a GH-releasing hormone
(GHRH)–arginine test 6 months post SAH. Primary outcome was the diagnostic value of a ghrelin test
compared with the GHRH–arginine test in the diagnosis of GHD. The secondary outcome was to assess
the safety of the ghrelin test, including patients’ comfort, adverse events, and idiosyncratic reactions.
Results: Forty-three survivors of SAH were included (15 males, 35%, mean age 56.6G11.7). Six out of
43 (14%) SAH survivors were diagnosed with GHD by GHRH–arginine test. In GHD subjects, median
GH peak during ghrelin test was significantly lower than that of non-GHD subjects (5.4 vs 16.6,
PZ0.002). Receiver operating characteristics analysis showed an area under the curve of 0.869.
A cutoff limit of a GH peak of 15 mg/l corresponded with a sensitivity of 100% and a false-positive rate
of 40%. No adverse events or idiosyncratic reactions were observed in subjects undergoing a ghrelin
test, except for one subject who reported flushing shortly after ghrelin infusion.
Conclusion: Owing to its convenience, validity, and safety, the ghrelin test might be a valuable GH
provocative test, especially in the early phase of SAH.
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The incidence of spontaneous subarachnoid hemor-
rhage (SAH) in The Netherlands varies between
5.7/100 000 subjects per year for men and
9.9/100 000 subjects per year for women. About 50%
of SAH patients do not survive (1, 2). Those who do
survive SAH have high rates of functional limitations
that could lead to impaired quality of life, fatigue,
decreased mobility, and loss of motivation. These
symptoms could be caused by growth hormone defici-
ency (GHD) (3).
The prevalence of hypopituitarism after SAH varies
between 0 and 55%, with GHD in 0–29% being the
largest deficit among all SAH patients (3, 4, 5, 6, 7, 8, 9,
10, 11, 12). This neuro-endocrine dysfunction may
result from the hypothalamic/pituitary system being
damaged as a result of post hemorrhagic complications,
e.g. local tissue pressure, toxic effects of the extravasated
blood, ischemia, hydrocephalus, or local destruction
during cerebral surgery.ne.orgGHD is diagnosed by a dynamic stimulatory test, as
standard serum insulin-like growth factor 1 (IGF1) tests
cannot discriminate between sufficient and insufficient
GH secretion (13). Currently, the gold standard for the
diagnosis of GHD is the insulin tolerance test. As this
test is contra-indicated in the elderly and in patients
with ischemic heart disease and seizures, it is regularly
replaced by the GH-releasing hormone (GHRH)–
arginine test, which is well-validated in adults (13).
However, as both tests are burdensome and limited by
side effects such as vasodilatation and paresthesia (14),
they are not useful in the early phase after SAH where
these side effects may be confused with the compli-
cations of SAH such as delayed cerebral ischemia which
need proper treatment.
It might be possible to diagnose GHD occurring
shortly after SAH by combining early hormonal
screening with GH stimulation testing. By its binding
to the GH secretagogue receptor-type 1a (GHSR-1a),
ghrelin has a strong GH-releasing activity, and can be
used as a diagnostic test. A ghrelin test is not limited byThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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adrenocorticotrophin (ACTH) (15). As there is little data
describing the use of ghrelin as a GH-stimulating
diagnostic test, the aim was to determine the diagnostic
value of a ghrelin test shortly after SAH to identify
subjects with GHD and to define the cutoff limit of the
GH peak below which GHD is confirmed.Subjects and methods
Study design
This study was part of the HIPSS (hypopituitarism in
patients after subarachnoid hemorrhage study), a
prospective single-center observational cohort study at
the Erasmus University Medical Center Rotterdam. It was
approved by the Local Medical Ethical Committee (METC).
All patients gave written informed consent. Adverse
events were registered and reported to the Central
Committee for human scientific research (CCMO).Subjects
Included in this study were all patients with aneurysmal
SAH, aged R18 years. All patients included in thisTable 1 Baseline characteristics and results of dynamic
Value
SAH patients with
GHRH–arginine
Sex (male) 15 (35)
Age (years) 56.6G
BMI 25.3G
!25 kg/m2 22 (51)
25–30 kg/m2 17 (40)
O30 kg/m2 4 (9)
WFNS
I 17 (40)
II 15 (35)
III 3 (7)
IV 5 (11)
V 3 (7)
Location of aneurysm
Anterior circulation 24 (56)
Posterior circulation 19 (44)
Aneurysm treatment
Endovascular treatment 37 (86)
Clipping 6 (14)
None 0
Hydrocephalus 19 (44)
Delayed cerebral ischemia 3 (7)
GH peak ghrelin test (mg/l) 15.3 (1.6–
GH response!5 mg/l 6 (14)
Baseline IGF1 SDS (95% CI) K0.06 (K2.
GH peak GHRH–arginine test (mg/l) 18.1 (2.4–
Insufficient GH response 6 (14)
6-month IGF1 SDS (95% CI) K0.7 (K2.
GH, growth hormone; GHRH, GH-releasing hormone; SAH, suba
Surgeons grading system for subarachnoid haemorrhage scale.
aUnless otherwise specified.
bExpressed as median (range).
cExpressed as mean (95% CI).
www.eje-online.orgstudy were treated for SAH before inclusion. They were
dismissed from the intensive care unit (ICU) and
admitted to the Department of Neurology of the
Erasmus Medical Center between June 2009 and June
2012. We excluded patients with any hypothalamic/
pituitary disease, former cranial irradiation, prior
significant head trauma, or any other medical condition
or laboratory abnormality that may have interfered
with the outcome of the study.Clinical definitions and outcome measures
The primary outcome was to compare the ghrelin test
with the GHRH–arginine test in terms of their value for
the diagnosis of GHD. The secondary outcome was to
assess the safety of the ghrelin test, including patients’
comfort, adverse events, and idiosyncratic reactions.
The diagnosis of SAH was confirmed by computerized
tomography (CT) or lumbar puncture. Localization of
the aneurysm was determined by CT angiography
or a digital subtraction angiography. We defined GH
deficiency (GHD) as an insufficient GH response to a
GHRH–arginine test, assessed at 6 months after SAH.
We used the following cutoff limits to define GHD
for the GHRH–arginine test: for subjects with a BMItests of included and excluded survivors.
s are expressed as n (%) of subjectsa
ghrelin test and
test (nZ43)
Excluded SAH patients in the
current study (nZ41)
9 (22)
11.7 56.3G11.8
3.1 24.8G4.2
23 (56)
12 (29)
6 (15)
21 (51)
10 (24)
0
6 (15)
4 (10)
25 (61)
16 (39)
29 (71)
11 (27)
1 (2)
13 (32)
5 (12)
117)b nZ15, 19.3 (8.2–35.4)b
0
1; 1.94)c
104)b nZ10, 23.2 (4.6–114.0)b
2 (5)
56; 1.16)c
rachnoid hemorrhage; WFNS, World Federation of Neurologic
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between 25 and 30 kg/m2, a peak GH!8 mg/l; and for
subjects with a BMIO30 kg/m2, a peak GH!4 mg/l (13).
To rule out interference of other hormonal deficiencies,
we simultaneously measured basal hormone levels
including cortisol, free thyroxin, thyroid-stimulating
hormone, prolactin (PRL), IGF1, and IGF binding
protein 3, in men and women; testosterone in men;
and estradiol, follicle-stimulating hormone, and luteiniz-
ing hormone in women. IGF1 was assessed by immulite
2000 (DPC Biermann GmbH/Siemens, Fernwald,
Germany), a solid-phase, enzyme-labeled chemi-
luminescent immunometric assay, with an intra-assay
variability of 2–5%, and an inter-assay variability of
3–7% (16), we calculated IGF1 mean SDS (17). IGFSDS
are depicted in Table 1.241 patients admitted
with SAHAcute phase
A ghrelin test was assessed in a fasting patient at rest,
during admission after SAH. BMI was calculated from
height and body weight (18). At baseline, we measured
GH and cortisol, and then infused 1 mg/kg body weight
acylated ghrelin. GH and cortisol were measured after 30
and 60 min. A recent study has shown that individual
peak GH response to ghrelin occurred in all subjects
between 15 and 45 min with a curve maximum at 30 min
after ghrelin test, in GHD and non-GHD patients (19).193 discharged from
ICU
48 death on ICU
51 fulfilling
exclusion criteria
38 refusal toSix months post-SAH
A GHRH–arginine test was assessed at the research unit
6 months after SAH. GH was measured, followed by
infusion of 1 mg/kg body weight GHRH and 0.5 mg/kg
arginine within 30 min. GH was assessed every 5–15 min.participate
20 discharged
before inclusion
84 included in the
HIPSS
15 only ghrelin
test
10 only GHRH–
arginine test
16 no GH
stimulation testStatistical analysis
Data were expressed as meanGS.D. for normal distributed
variables or as median (ranges) for nonnormative vari-
ables. To evaluate differences in GH peak between GHD and
non-GHD subject, Mann–Whitney U test was assessed. To
determine the value of applying a ghrelin test shortly after
SAH to identify subjects with GHD, the sensitivity,
specificity, and positive and negative predictive values
were calculated using receiver operating characteristics
(ROC) analysis. The reference test for the detection of GHD
is the GHRH–arginine test. In addition, the likelihood
ratios of a positive ghrelin test and of a negative ghrelin test
were calculated. All statistical analyses were performed
with SPSS version 20.0 (SPSS, Inc., Chicago, IL, USA).43 included in the
current study
Figure 1 Inclusion criteria for subjects. SAH, subarachnoid
hemorrhage; ICU, intensive care unit; GH, growth hormone; GHRH,
GH-releasing hormone; HIPSS, hypopituitarism in patients after
subarachnoid hemorrhage study.Results
Patients
Out of 241 patients admitted to the ICU with the diagnosis
of SAH, 193 survived. Fifty-one patients did not fulfill theinclusion criteria, 38 refused to participate, and 20
patients were discharged before the inclusion was fulfilled.
Eventually, 84 patients were included in the HIPSS study
(Fig. 1). Fifteen patients had a ghrelin test and no GHRH–
arginine test. They found the endurance of the dynamic
tests too strenuous. At the start of the study, ghrelin test
was not at our disposal; so ten patients only had a GHRH–
arginine test but no ghrelin test, and 16 patients did not
give us permission to perform the dynamic tests.
In 43 patients, both the ghrelin test and the GHRH–
arginine test were assessed and therefore the data of
43 patients were analyzed in the current study. Patient
characteristics are outlined in Table 1. Median time
between occurrence of SAH and ghrelin test was
18 days. Patient characteristics of excluded and
included subjects did not differ significantly (sex: male,
9/41 (22%) vs 15/43 (35%), PZ0.142; mean age, 56.3
vs 56.6 years, PZ0.912).Outcome
Six out of 43 (14%) SAH survivors were diagnosed with
GHD by the GHRH–arginine test. The median GH peakwww.eje-online.org
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Table 2 Summary statistics for various GH cutoff values for the
ghrelin test predicting GH deficiency.
GH cutoff for
ghrelin test
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
2.6 17 100 100 88
3.9 33 100 100 90
4.8 50 97 75 92
6.1 67 92 57 94
11.4 83 73 33 96
15.0 100 60 29 100
20.0 100 38 21 100
30.4 100 16 16 100
GH, growth hormone; PPV, positive predictive value; NPV, negative
predictive value.
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and 6.2 mg/l during the GHRH–arginine test (Fig. 2). In
GHD subjects, median GH peak during ghrelin test was
significantly lower than that of non-GHD subjects
(5.4 (range 1.6–14.6) vs 16.6 (4.1–117), PZ0.002).
We observed a low cortisol level in one patient (2%)
during ghrelin testing. This subject who was re-tested
using the synacthen-test did not reveal a secondary
hypocortisolaemia. Three male patients with GHD also
had a hypogonadotropic hypogonadism. Another nine
patients in this study had hypogonadotropic hypogo-
nadism after 6 months.
ROC analysis showed an area under the curve of
0.869. Table 2 gives an overview of sensitivity,
specificity, positive predictive value, and negative
predictive value for different cutoff limits of the GH
peak during a ghrelin test. A sensitivity of 100%, which
is needed to diagnose every GHD subject, gives a false-
positive rate of 40% (1-specificity), belonging to a cutoff
of 15 mg/l (Table 2). A cutoff of 11.4 mg/l gives the
optimal combination of the highest sensitivity (83%)
and the highest specificity (73%).Adverse events/safety measures
Only one subject reported an adverse effect, i.e. flushing
starting shortly after ghrelin infusion, which lasted for
30 min. During this period, we monitored heartGH
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Figure 2 GH peak in GH-deficient subjects vs non-GH-deficient
subjects. GH, growth hormone; GHRH, GH-releasing hormone.
www.eje-online.orgfrequency and blood pressure, which remained stable.
No adverse events or idiosyncratic reactions were
reported by or observed in the other subjects under-
going a ghrelin test.Discussion
Ghrelin testing is a safe and valid alternative in the
diagnosis of GHD shortly after SAH. Other current
available GH provocative tests might be burdensome
and their use is limited in SAH survivors because of
their possible side effects.
Ghrelin, a 28-amino-acid peptide hormone, is
predominantly produced by the stomach, stimulates
food intake and a positive energy balance, and plays an
important role in fat metabolism (20). Besides, ghrelin
has strong GH-releasing activity by binding to the
GHSR-1a. Apart from stimulating GH secretion, ghrelin
exhibits hypothalamic activities resulting in the stimu-
lation of PRL and ACTH secretion (20). Previous studies
described the use of ghrelin as a GH stimulation test,
when combined with GHRH, illustrating a strong and
potent GH-releasing activity due to the synergistic
effects of ghrelin and GHRH (21, 22, 23, 24). In
addition, administration of ghrelin alone illustrated a
GH release with a clear dose–response curve in normal
subjects (22, 25). In GHD subjects, GH response was
significantly lower than that in normal subjects,
illustrating the value of a ghrelin test in diagnosing
GHD (24). The use of GH-releasing peptide 6, which
is an artificial hexapeptide activating the GHSR1a, in
combination with GHRH, has been described as a potent
GH-provocative test in several studies investigating
pituitary dysfunction after traumatic brain injury
(26, 27, 28). In the current study, a ghrelin test was
assessed shortly after SAH and illustrated a significantly
lower GH peak in GHD subjects compared with non-
GHD subjects. ROC analysis showed a high accuracy of
the ghrelin test when compared with GHRH–arginine
test. The GHRH–arginine test, however, is inconvenient
in SAH patients because of its known side effects such as
vasodilatation and paresthesia (14). A more safe andDownloaded from Bioscientifica.com at 09/04/2019 12:21:44PM
via free access
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preferred, especially in disabled patients who are
critically ill. Another known side effect of GHRH
administration is transient facial flushing, which occurs
in 25% of the patients (14). In our view, this side effect
might be related to fluctuating blood pressure, which is
also undesirable in patients in the early phase after SAH.
In a recent paper published by Gasco et al. (19),
ghrelin test proved to be a valid diagnostic test for GHD
in adults with reliable cutoff limits in lean and
overweight patients. Furthermore, they concluded that
obesity has an impact on the GH response to ghrelin,
lowering the predictive value of the test in these
patients, so caution must be taken when it comes to
interpreting ghrelins test in obese patients. However,
obesity has an impact on almost all dynamic GHD tests
(29). They also described that facial flushing occurred in
a smaller group of patients after ghrelin test compared
with GHRH–arginine test. Other adverse events of
ghrelin administration have not been described so far
except for patients receiving more than 250 mg of
ghrelin, who reported transient hyperhydrosis (22, 25).
Beside its convenience, the ghrelin test would be
preferred above the GHRH–arginine test because, by
stimulating ACTH release, adrenal function could be
evaluated. The prevalence of adrenocorticotropic defici-
ency following SAH varies from 0 to 40% (6, 7, 8, 12)
and could lead to life-threatening conditions if
untreated. This elucidates added value of the ghrelin
test as it can be used to detect a secondary adrenocorti-
cotropic deficiency early after SAH. However, as the
ACTH-releasing activity is less potent, higher ghrelin
doses may be needed in order to discriminate between
sufficient and insufficient cortisol response (24). There-
fore, the evaluation of adrenal function by ghrelin
testing should be elucidated in further studies.
We observed that a second confirmatory test was
needed to confirm true GHD in patients who had low GH
response to the ghrelin test. A recent study by Gardner
et al. (30) also concluded that real GHD in SAH patients
has to be confirmed by two different stimulation tests and
by the application of BMI specific cutoffs. Based on these
findings, we recommend the usage of two different
stimulation tests for the confirmation of true isolated GHD.
The limitation of this study was that cutoff limits for
the ghrelin test could not be defined, as only six patients
had been diagnosed with GHD. Fortunately, the cut off
values for ghrelin test have been recently published by a
different group of investigators (19).
Secondly, the time between GH stimulation tests
could be an important confounder because hypopitui-
tarism in the acute phase has been described to resolve
in the post-acute phase (11, 31). This might be caused
by the SAH or SAH’s related complications. Further-
more, the fact that the subjects are critically ill could
also have a significant impact on the results of the
ghrelin test. However, some studies have shown that in
contrast to both hypogonadism and hypocortisolismthat can normalize during follow-up, GHD prevalence
remained stable until 1 year after SAH (4, 32). Ideally,
multiple GHD tests in this early phase could exclude
these possible confounders; however, it is not feasible to
perform multiple tests in critically ill SAH patients.
In conclusion, the ghrelin test discriminated between
GHD and non-GHD survivors of SAH and displayed a
high accuracy compared with the GHRH–arginine test.
Owing to its convenience, validity, and safety, the
ghrelin test is a novel GH provocative test that can be
used as a screening tool for the prediction of late GHD in
SAH patients.Declaration of interest
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